SCHEMBL7523907

SCHEMBL7523907

CC(=O)N(c1ccc(C(=O)O)cc1)c1ccc(N(C(C)=O)c2ccc(C=Cc3ccccc3)cc2C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.48
HNF4A P41235 1/20 0.48
SRD5A1 P18405 1/20 0.42
SRD5A2 P31213 1/20 0.42
CASP3 P42574 2/20 0.42
KMT2A Q03164 2/20 0.42
SENP8 Q96LD8 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
SENP6 Q9GZR1 2/20 0.42
MEN1 O00255 1/20 0.42
APAF1 O14727 1/20 0.42
TDP2 O95551 1/20 0.42
NSD2 O96028 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
UBA2 Q9UBT2 1/20 0.42
PTPN6 P29350 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7523894 1.00 PTPN1 (0.48) PTPN1HNF4ASRD5A1SRD5A2CASP3
SCHEMBL7531126 0.84 PTPN1 (0.63) PTPN1HNF4APTPN6PTPN2RARA
SCHEMBL7531117 0.84 PTPN1 (0.63) PTPN1HNF4APTPN6PTPN2RARA
SCHEMBL7528656 0.83 SNCA (0.47) PTPN1HNF4ASRD5A1SRD5A2KMT2A
SCHEMBL7528666 0.83 SNCA (0.47) PTPN1HNF4ASRD5A1SRD5A2KMT2A
SCHEMBL7523901 0.80 PTPN1 (0.47) PTPN1HNF4ASRD5A1SRD5A2CASP3
SCHEMBL7646353 0.80 PTPN1 (0.40) PTPN1HNF4ASRD5A1SRD5A2CASP3
SCHEMBL7646355 0.79 ALDH1A1 (0.47) PTPN1HNF4AKMT2AMAPTSMN1; SMN2
SCHEMBL7530268 0.78 APP (0.40) PTPN1HNF4ACASP3KMT2ASENP8
SCHEMBL7530259 0.78 APP (0.40) PTPN1HNF4ACASP3KMT2ASENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 PTPN1 1380/4885HNF4A 425/4885SRD5A1 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.